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Summary
Fanconi anemia (FA) is an autosomal recessive disease
characterized by progressive pancytopenia, congenital
malformations, and predisposition to acute myeloid leu-
kemia. At least five complementation groups
(FA-A–FA-E) have been identified. The relative preva-
lence of FA-A has been estimated at an average of ∼65%
but may widely vary according to ethnic background.
In Italy, 11 of 12 patients analyzed by cell-fusion studies
were assigned to group FA-A, suggesting an unusually
high relative prevalence of this FA subtype in patients
of Italian ancestry. We have screened the 43 exons of
the FAA gene and their flanking intronic sequences in
38 Italian FA patients, using RNA-SSCP. Ten different
mutations were detected: three nonsense and one mis-
sense substitutions, four putative splice mutations, an
insertion, and a duplication. Most of the mutations are
expected to cause a premature termination of the FAA
protein at various sites throughout the molecule. Four
protein variants were also found, three of which were
polymorphisms. The missense mutation D1359Y, not
found in chromosomes from healthy unrelated individ-
uals, was responsible for a local alteration of hydro-
phobicity in the FAA protein, and it was likely to be
pathogenic. Thus, the mutations so far encountered in
the FAA gene are essentially all different. Since screening
based on the analysis of single exons by genomic DNA
amplification apparently detects only a minority of the
mutations, methods designed to detect alterations in the
genomic structure of the gene or in the FAA polypeptide
may be helpful in the identification of FAA mutations.
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Introduction
Fanconi anemia (FA) is an autosomal recessive disease
characterized by progressive bone-marrow failure, var-
ious birth defects, and a markedly increased incidence
of malignancies (Butturini et al. 1994). Cells cultured
from FA patients exhibit an increased level of sponta-
neous chromosomal aberrations and are hypersensitive
to the clastogenic effect of cross-linking agents, such as
mitomycin C and diepoxybutane (DEB). The latter fea-
ture is used to confirm the FA diagnosis (Auerbach
1993).
FA is genetically heterogeneous: at least five comple-
mentation groups (FA-A–FA-E) have been identified
(Strathdee et al. 1992a; Joenje et al. 1995), each group
presumably corresponding to a separate disease gene
(FAA–FAE) (Buchwald 1995). The relative prevalence
of the FA-A subtype has been estimated to be
60%–66%, as determined by complementation analysis
and homozygosity mapping (Buchwald 1995; Gschwend
et al. 1996). The relative prevalence of FA-A is unusually
high in Italy, since 11 of 12 Italian patients analyzed by
complementation studies were type FA-A (Savoia et al.
1996).
FAC, which maps to chromosome 9q22.3, was the
first gene to be cloned (Strathdee et al. 1992a; 1992b)
whereas FAA has only recently been identified (FAB
Consortium 1996; Lo Ten Foe et al. 1996a). The FAA
gene has an open reading frame of 4,365 bp that encodes
a protein of 1,455 amino acids. It contains 43 exons
and spans ∼80 kb of genomic DNA on chromosome
16q24.3 (Ianzano et al. 1997), between microsatellites
D16S3026 and D16S303 (Pronk et al. 1995; FAB Con-
sortium 1996). FAA and FAC have no significant ho-
mology to any known proteins or to each other and may
therefore represent component elements of a novel path-
way(s) involved in the prevention of DNA damage.
To date, eight different mutations of the FAA gene
have been identified, by use of patient RNAs, by SSCP
and the protein-truncation test. Five were deletions of
one or more exons, which are probably genomic dele-
tions. Another was a TTGG deletion in exon 13, and
two were substitutions at different residues in the donor
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splice site of intron 7, leading to the utilization of a
downstream cryptic splice signal. All, except for the in-
frame deletion of exons 16 and 17, caused a shift of the
open reading frame and a premature truncation of the
FAA protein (FAB Consortium 1996; Lo Ten Foe et al.
1996a).
In order to screen the FAA gene for mutations from
genomic DNA, intronic sequences were used to set up
PCR and to amplify the 43 exons in 38 patients of Italian
ancestry. Ten new mutations and three polymorphisms
were identified by RNA-SSCP.
Patients and Methods
Patients
Thirty-eight unrelated FA patients, all of Italian an-
cestry, had been previously diagnosed on the basis of
clinical symptoms in combination with the hypersensi-
tivity to DEB, as determined in a standard chromosomal-
breakage test (Auerbach 1993). Lymphoblastoid cell
lines were established from 15 of these patients. DNA
samples was extracted from cell lines or peripheral blood
and were designated, respectively, with “VU” and “FA”
numbers. Except for VU578, patients designated as
“VU” had been previously reported with clinical symp-
toms and results from a functional complementation
analysis, and 11 of them had been assigned to group
FA-A (Savoia et al. 1996).
RNA-SSCP and Direct Sequencing
High-molecular-weight DNA was prepared from pe-
ripheral blood or lymphoblast cell lines by use of pro-
teinase K (Sambrook et al. 1989). The FAA-gene exons
containing the coding region and the flanking regions
(Ianzano et al. 1997) were amplified by use of a set of
oligonucleotides shown in table 1. PCR was performed
in 50 ml containing 50 ng of DNA, 15 pmol of each
primer, 2.5 mM MgCl2, 10 mM Tris-HCl (pH 7.5), 50
mM KCl, 0.01% Tween-20, 0.01% gelatin, 0.01%
NP40, and 2 units of Taq polymerase. Initial denatur-
ation was for 6 min at 85C, followed by amplification
for 30 cycles, each with denaturation for 30 s at 94C,
annealing for 30 s at the temperature indicated in table
1, and extension for 30 s at 72C. The amplified products
were then used for RNA-SSCP screening (Sakar et al.
1992). Transcription was performed with 14 U of T7
RNA polymerase in a final volume of 10 ml containing
TSC (Promega), 5 nmol of each ribonucle-1 # buffer
oside, 10 U of RNasin, and 0.2 ml of [a-35S]UTP (11,000
Ci/mmol), and the product was loaded onto a nondena-
turing polyacrylamide gel containing 10% glycerol. Di-
rect sequencing was performed either according to the
methods recommended by United States Biochemicals or
by use of a fluorescence-labeled dideoxy-nucleotide ter-
mination method (dye terminator) in an automated
DNA sequencer 373A (ABI).
cDNA Synthesis and PCR
Total RNA from lymphoblasts was prepared by use
of guanidinium thiocyanate and by layering the cell
homogenate on a cushion of a dense solution of CsCl
(Chirgwin et al. 1979). RNA was transcribed by use of
2.5 mM random hexamer, (BRL kit), 10 M5 # buffer
DTT, 500 mM dNTP, 1 U of RNase inhibitor/ml, and 10
U of reverse transcriptase (RT)/ml, for 1 h at 37C. PCR
for the detection of altered splicing was performed as
above, with the following two pairs of primers: 597F
(5′-C CAT CCC GAC ATG CAT GCT G-3′) (exon 7)
and 1011R (5′-AG ATG CTT TCA GCA CAG GGC-3′)
(exon 11–12), for the skipping of exon 9, and 2609F
(5′-TC CTC ATG TTC AGA TTG TTC-3′) (exon 28)
and 2974R (5′-G GAA ATC CAT CAG TGC GTT G-
3′) (exon 30), for the alternative cleavage of exon 28.
PCR products were purified, subcloned into the pCRTM
vector (Invitrogen), and sequenced by dye-primer cy-
cle–sequencing method in an automated DNA sequencer
373A (ABI).
Results
Mutation analysis of the FAA gene was performed in
38 FA Italian patients. All patients were diagnosed on
the basis of clinical symptoms, such as bone-marrow
failure, congenital malformations, and hypersensitivity
to DEB, as determined in a standard chromosomal-
breakage test (Auerbach 1998). Eleven of these patients
belonged to group FA-A, as determined by complemen-
tation analysis (Savoia et al. 1996).
Since complementation analysis is a technically de-
manding and time-consuming procedure, a linkage anal-
ysis might be performed to exclude unclassified families
from complementation subtypes FA-A and FA-C , by use
of markers localized at chromosomes 16q24.2 and
9q22.3, respectively. Of the 27 unclassified families, 11
were eligible for linkage studies, and results were com-
patible with linkage on chromosome 16q24.3. Three of
these families were also excluded from subtype FA-C
and, given the high relative prevalence of FA-A in Italy
(Savoia et al. 1996), were likely to be group FA-A (Sa-
voia et al. 1997). The other 16 FA DNAs—8 from sin-
gleton families and 8 from FA patients whose parents’
DNAs were not available—were also included in this
study, since most of these patients were likely to be
FA-A.
Each exon of the FAA gene was amplified from ge-
nomic DNA and was analyzed by RNA-SSCP. With this
approach, several instances of sequence variations in the
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Table 1









1 T7-gccgcagccaataggaaggc gatcggggaaccggcgaaaccg 60 241
2 T7-tttcgaaccgacttctctcc gaactcccgggctcaggcgac 60 303
3 ggagcttgaattttttaaatgg T7-gtcacacaaacatcccatag 56 315
4 gtgctgcatcttaaaataaggc T7-aacgggcaggtttcctcatc 56 300
5 gcaaagatgaggaaacctgc T7-ctgttgcctccatccagatc 56 304
6 ggcatggttaagaacctaag T7-aaacccgtctgattctggg 56 374
7 tgatgggatttagttgagcc T7-tgagttttacccaagaaccc 58 221
8 T7-tgaagtggatggtctgtgcc acacttggaataaggacggct 56 241
9 T7-attctcttgtgtgatgcagg tacctcaaatggaaaggcag 56 219
10 tgaagtggatctgttgtctga T7-taatttggcagacacctccc 58 241
11 T7-tttcctgacccctctttctg agcgttaccaaggcaacaagg 56 239
12 cccacaactttttgatctctg T7-agacatccctgaacctctcg 56 267
13 gtcatctgtcgcacattggtt T7-tacacacactcttgaccac 58 267
14 ggaatacttgatcacccagc T7-aaagctgacagcaaggttgc 58 361
15 T7-tctctccacacaggacactg ttggggaggccaaggcagtc 60 289
16 agcactgtggatgttggaag T7-agtttctgctgggacaggtg 60 257
17 tcccagcagaaactgctttg T7-gaggcaagaccagacatgag 57 254
18 acaaggaagcacaggttgag T7-acatactgcaggcatcagag 56 275
19–20 tccactctctgaaacaccgg T7-acgattcttcgcattgtcag 56 375
21 caggctcatactgtacacag T7-agcacaacagacactcaag 58 304
22 ttgagtgtctttccatctgg T7-agccacagagctccaaccac 58 239
23 tctctaggccgcagctgtat T7-ctaatgcctctgcctaatgg 56 291
24 T7-caaagcagaattgcgatgtc cggagacgagctcatgagtcc 56 290
25 ggactgaatggctagtactg T7-acgaattgagaagtagcagc 58 229
26 T7-attcgtcttcagtgccctgg atcaaacgagcatgtgtcact 58 350
27 ccatccagttcggaatgcact T7-agctgcgtaaacctgaaacg 58 286
28 tgctcagccactcacagtg T7-agacagtcggcacacac 60 412
29 ggaactctcagctgcaatttc T7-ccagggtagctcttttcaac 56 261
30 T7-ctgtgtgtcccttactatgg tgtccctccagagaacccta 53 285
31 T7-aggagaactgggaacttcag cacgcggcttaaatgaagtg 58 224
32 ccgactggctgggcagtgag T7-ctaggaccgtcatgagatgct 58 322
33 cttgggaaggagcagagtgt T7-ttcacacggtcagtacacgc 58 285
34 agcagccactctgcatgttg T7-ggtttgtgaggacccacaac 58 265
35 tcctgtgagttccttcactc T7-catccccaaaacagaacacc 58 240
36 ctgtagtggcctgtaggagca T7-agcaagccagggtgtttagg 58 322
37 aggacttggtttctatggcg T7-ctgattgaaaccaagcttgc 58 285
38 T7-gaatgacagcacaggtaatt gctcctgagctagtctggaa 58 242
39 agcaccaggtcggccattct T7-tgcaagatgcctctg 56 233
40 ccagggtacacgtcccgacc T7-cagacaacccttcccatctg 58 284
41 T7-gtgctacctttccagcagtc ccatagtctgcatgctgt 56 325
42 acagcatgcagactatgg T7-ggcagctgtcaattctcatg 60 251
43 T7-ctgtggtctgaggcctagtg cactaaagcagtcgaggaga 60 300
a T7  T7 tail (TAA TAC GAC TCA CTA TAG GG).
b Includes 20-bp T7 tail.
FAA gene were detected: three nonsense mutations, four
alterations in splice sites, a duplication, an insertion, and
four missense substitutions (tables 2 and 3).
Nonsense Mutations
Three CrT transitions at positions 790, 2005, and
2314 led to the substitution of a glutamine with a stop
codon and, therefore, to a premature truncation of the
FAA protein in exons 8, 22, and 25, respectively, in three
patients.
The only child of a consanguineous marriage (VU388)
was homozygous for the mutation 790CrT (Q264X).
The second patient, FA38, was a compound heterozy-
gote for a paternally transmitted mutation, 2005CrT
(Q669X). The transition 2314CrT (Q772X), homo-
zygous in patient VU268, created a restriction site for
MaeI; restriction analysis of the family members showed
that both parents carried the substitution (fig. 1). The
results were consistent with haplotype data, since the
affected sib presented autozygosity at six microsatellite
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Table 2
Mutations of the FAA Gene
Patient
Complementation
Groupa DNAb RNA/Protein Protein Segregationc
VU388d FA-A 790CrT
(homozygous)
Q264X 8 P and M
VU330 FA-A IVS93delA
(homozygous)




























a Patients were classified as FA-A by complementation analysis (Savoia et al. 1996) and as non–FA-C by linkage exclusion on chromosome
9q22.3 (Savoia et al. 1997); ND  not determined by either complementation or linkage analysis (i.e., singleton families or parents’ DNA not
available).
b The A of the ATG of the initiator Met codon is reported as nucleotide 1.
c P  paternal transmission of mutation; M  maternal transmission of mutation; and ND  not determined.
d Patient had homozygous microsatellites surrounding the FAA locus.
Table 3










796A/G MaeIII T/A266 9 .29
1501G/A MspI G/S501 16 .40
2426G/A BstNI G/D809 26 .30
a The A of the ATG of the initiator Met codon (FAB Consortium
1996) is reported as nucleotide 1.
loci, from D16S413 to the telomere of chromosome
16q24.3 (Savoia et al. 1997).
Splice-Site Mutations
Four putative splice-site mutations were identified in
the donor splicing site of introns 9, 10, 14, and 28. In
order to verify the alterations at the RNA level, the
cDNA, when available, was amplified and sequenced.
Patient VU330 was found to be homozygous for an
A deletion (IVS9delA3) in the donor splice site of exon
9. The prediction of the donor splice sites was calculated
by the scores for both the wild-type TTgtaagt signal and
the mutated TTgtagtt signal, which were 79 and 54,
respectively (Shapiro and Senapathy 1987; Ianzano et
al. 1997). To determine whether the deletion was re-
sponsible for a defective cleavage of intron 9, RT-PCR
was performed with primers in exons 7 and 11. A prod-
uct of reduced size, corresponding to a 34-bp deletion
of exon 9, was detected in the patient (fig. 2). The faint
major band detected in all samples corresponded to the
insertion of an alternatively spliced exon (exon 10a; L.
Ianzano, unpublished data). The absence of exon 9 cre-
ated a shift in the open reading frame and a stop codon
19 amino acids downstream. Sequence analysis revealed
the mutation to be present in both parents but not in
the unaffected sister. The patient was, however, heter-
ozygous for all the informative microsatellite markers
at 16q24.3, suggesting that either the mutation occurred
independently on two different chromosomes or that
several recombination events had rendered the founder
haplotype unidentifiable.
Patient VU262 was heteroallelic for a GrT transver-
sion at the donor site of intron 10 (IVS101GrT). The
mutation was not inherited by the mother, who was not
a carrier (the father’s DNA was not available), and it
was transmitted to the affected brother as well. The mu-
tation was expected to destroy the splice site and effec-
tuate either the skipping of exon 9 or the recognition of
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Figure 1 Identification of the 2314CrT mutation.A,Nucleotide
sequence analysis of the PCR-amplified fragment of exon 24 from a
normal control (wt) and patient VU268 (m). The substitution created
a restriction site for MaeI (underlined). B, Diagram of the localization
of MaeI sites in wild-type (wt) and mutated (m) alleles and of digestion
of the PCR products from family members. Lane nd, Undigested PCR
product. Lanes M, DNA size marker (1-kb ladder).
cryptic splice signals. However, RT-PCR and sequencing
analysis did not allow the identification of any altered
product. The hypothesis that the mutation may lead to
an unstable and undetectable mRNA has not been
investigated.
The homozygous transversion IVS141GrC in the
donor splice site of intron 14 would be expected to de-
termine an alternative splicing event; however, this could
not be confirmed, since RNA of FA25 was not available.
The patient was homozygous at microsatellites in
16q24.3 (Savoia et al. 1997), and haplotype data were
consistent with the segregation of the mutation in the
four healthy sisters and the mother. However, since the
father’s DNA was not available, we cannot exclude a
paternal genomic deletion as the second pathogenic FA
allele in this family.
In the 5′ region of intron 28, a 60-bp repeat was pres-
ent twice, at residues 1–60 and 84–133. In pa-
tient VU578, a homozygous transversion CrG
(IVS2883CrG) at position 83 of intron 28 created a
cryptic donor site AGgtagg with a score of 86, calculated
according to the method of Shapiro and Senapathy
(1987), higher than the score of 76 for the normal-signal
ACgtagg (Ianzano et al. 1997). Since the mutation was
only paternally inherited, the second FA allele might be
a maternal genomic deletion. We verified the possibility
of an alternative cleavage of intron 28 by using RT-PCR
with primers in exons 28 and 30 (fig. 3). In the normal
control, two bands were observed, the shorter one (366
bp) being the product expected and the longer one (484
bp) corresponding to the insertion of an alternatively
spliced new exon (exon 29a; L. Ianzano, unpublished
results). In VU578 we detected three products, 366, 449,
and 567 bp in size. Sequence analysis showed that the
intermediate band represented the mutated cDNA due
to the insertion, between exons 28 and 29, of the first
83 bp of intron 28; the major band contained the ad-
ditional exon 29a (fig. 3). The alternative splicing of
intron 28 led to the translation of 28 new amino acids
and a stop at codon 955 in the FAA gene. The apparent
ratio of the wild-type (366 bp) and the mutated (449
bp) alleles in VU578 was ∼1:10, suggesting that the splic-
ing machinery recognizes both the normal and the cryp-
tic donor site, but with a different efficiency.
Duplication and Insertion
A duplication and a single base insertion were detected
in one patient and in two patients, respectively. Patient
FA19 carried a paternally inherited heterozygous dupli-
cation of 19 bp, GA AAT TCA ACC TGA AGC TG
(residues 3012–2830), in exon 29, causing a shift of the
open reading frame and a stop codon four amino acids
downstream. An insertion of a single G at residue 3559
(3559insG) in exon 36 was detected in two unrelated
individuals, VU393 and FA37. This mutation, which
leads to a frameshift and a stop codon, was homozygous
in the first patient, the only child of a consanguineous
marriage, and was heterozygous in the other.
In the absence of functional data, it is difficult to de-
termine conclusively whether an observed variation in
sequence represents a pathogenic mutation. However,
the majority of sequence alterations described in this
paper are predicted to truncate the FAA protein and are
thus likely to represent pathogenic mutations. One hun-
dred chromosomes from healthy unrelated individuals
were analyzed for the presence of each variation, by
different approaches, such as restriction analysis, restric-
tion site–generating PCR (RG-PCR), or RNA-SSCP.
None of the previously described mutations was detected
in the normal controls (data not shown).
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Figure 2 Detection of the IVS93delA mutation. A, Sequence
analysis of the amplified product of exon 9 in all members of the
family. B, RT-PCR products resulting from use of primers in exons 8
and 11 of patient VU330 (lane 1), different lymphoblastoid cell lines
(lanes 2 and 3), and a negative control (lane 4). Lane M, DNA size
marker (1-kb ladder).
Figure 3 Identification of the alternative splicing of intron 28,
resulting from the IVS2883CrG mutation in patient VU578; results
shown are for RT-PCR using primers in exons 28 and 30 of the CaCo2
cell line (lane 1), VU578 (lane 2), and a negative control (lane 3). Lane
M, DNA size marker (1-kb ladder).
Missense Substitutions
Some amino acid substitutions were detected. Among
these, only one (D1359Y) was not found in non-FA chro-
mosomes, and it involved a change from a charged to
a hydrophobic amino acid. A local variation in hydro-
phobicity, with a possibly deleterious effect on FAA-pro-
tein activity was detected by the PC/GENE analysis pro-
gram. The other amino acid substitutions were more
conservative and were not predictive of any significant
conformational changes. In fact, T/A266, G/S501, and
G/D809 were found to be polymorphisms, as assessed
by restriction-enzyme analysis. The respective allele fre-
quencies, estimated for 100 chromosomes from unre-
lated individuals, are listed in table 3.
Discussion
Knowledge of the mutation spectrum occurring in the
FAA gene may contribute significantly to pathogenesis
studies in FA and may help to design mutation-screening
strategies. The identification of pathogenic mutations in
FA patients allows for the assignment of patients to com-
plementation group FA-A and thus removes the need for
a much more laborious complementation study. In ad-
dition, knowledge of the mutations allows for a rapid
prenatal diagnosis, as well as for carrier testing in the
FA families.
RNA-SSCP screening of all 43 exons of the FAA gene
led to the identification of nonsense mutations, altera-
tions in donor sites, an insertion, and a duplication, most
of which predict a premature truncation of the FAA
protein. Two mutations affecting the intronic sequences
led to splicing aberrations. In one family, a nucleotide
deletion in the donor splice site caused the skipping of
the respective exon. In another patient, an intronic sub-
stitution generated a cryptic splice site and an alternative
cleavage of the transcript, although a small amount of
the wild-type messenger was produced. It was found that
IVS101GrT did not alter the mRNA in two siblings.
However, an instability of the RNA carrying this mu-
tation cannot be excluded.
Consistent with linkage and haplotype analysis in Ital-
ian pedigrees, which revealed a high frequency of com-
pound heterozygotes and a wide variety of haplotypes
(Savoia et al. 1997), the results reported in this paper
suggest that different mutations characterize the Italian
FA alleles, whereas none of these seems to occur at a
high frequency. The degree of mutation homogeneity
was expected to be high in the genetic isolate of the
Brenta basin (Savoia et al. 1997). Unexpectedly, even
though patients VU330, VU268, and VU388 shared the
same haplotype, they were found to carry different mu-
tations, suggesting that different mutational events have
occurred on the same chromosome. Except for VU330,
who had two distinct haplotypes, the homoallelic pa-
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tients were either from a consanguineous marriage or
autozygous at the loci surrounding the FAA locus. The
other seven patients were compound heterozygotes;
however, in none of these has the second FA allele been
characterized.
Surprisingly, screening of all 43 exons of the FAA gene
has led to the identification of only 10 mutations, in 11
of 38 patients. This low number could be attributed to
several causes. First, FA is a genetically heterogeneous
disease (Strathdee et al. 1992a; Joenje et al. 1995), and
so some of the patients may in fact not belong to
group FA-A. However, since 11 patients were classified
as FA-A by complementation analysis but only four
(VU388, VU330, VU262, and VU268) have been char-
acterized for one or two mutations, the nonassignment
to FA-A group does not seem to be the reason for the
low mutation yield. Second, a subset of FA alleles in
certified FA-A patients might have escaped the screening
process, either because of the limitations of the technical
procedure or because of their localization in either in-
trons or the promoter region. Finally, evidence for ge-
nomic deletions has been reported previously (FAB Con-
sortium 1996). For example, in patient VU337, exons
18–21 were deleted in the RNA, and in situ hybridi-
zation indicated that one FA allele is a large genomic
deletion of the entire FAA gene (data not shown). It
might be that some factors, such as an intrinsic insta-
bility in the FAA region, might lead to genomic deletions
or other structural rearrangements of the gene. There-
fore, to increase the efficiency of mutation screens, a
different strategy may be useful, such as Southern blot-
ting, FISH analysis, and methods designed to detect al-
terations at the protein level (FAA antibodies or the pro-
tein-truncation test).
In the other cloned FA gene, FAC, a total of 10 path-
ogenic mutations have been identified (Strathdee et al.
1992b; Gibson et al. 1993, 1996; Murer-Orlando et al.
1993; Whitney et al. 1993; Verlander et al. 1994; Lo
Ten Foe et al. 1996b, and in press). Except for two amino
acid substitutions, the other sequence variations would
predict, as in FAA, premature terminations of the FAC
protein. However, a wider spectrum of FAC mutations
has to be expected, since only single mutations were
identified in several heterozygous patients. Indeed, since
a large number of the FA patients were unclassified, the
rate of mutations in the FAC gene may be underesti-
mated, since some alterations may have escaped the
screening procedures.
The FAA mutations described so far are widely dis-
tributed over the FAA gene, and all but one were found
only in single patients (FAB Consortium 1996; Lo Ten
Foe et al. 1996a). This situation hampers a detailed ge-
notype-phenotype correlation study, which would oth-
erwise be helpful in the identification of possible asso-
ciations with a mild or severe form of the disease. A
further difficulty is due to a wide clinical heterogeneity
in FA, not only among patients from different families
of the same complementation group A but also among
patients within one family (Savoia et al. 1996). However,
patients VU388, VU330, VU268, and VU393, homo-
zygous for a nonsense or frameshift mutation, have a
relatively severe phenotype, with multiple congenital
malformations and severe pancytopenia (Savoia et al.
1996). Continued screening for mutations may localize
critical domain or functional residues of the FAA protein
and, in this way, may help to provide a better under-
standing of the molecular pathogenesis in FA patients.
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